Response to therapy in demyelinating motor neuropathy.
We reviewed results of immunotherapy in patients with demyelinating motor neuropathy (DMN), and found that patients over 50 years of age at onset responded poorly, and younger patients responded variably to intervention. We suggest that patients with DMN be given a guarded prognosis, particularly if >50 years of age at onset.
Markson
L
L
The Toronto Hospital, General Division, Ontario, Canada.
Janzen
D
D
Bril
V
V
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D003711:Demyelinating Diseases / Q000628:therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000502:physiology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous